Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31151644 | 0.80 | CHRNB2 (0.36) | CHRNB2CHRNA4GAAALPGGFER | |
| SCHEMBL5821547 | 0.77 | DPP4 (0.38) | CHRNB2CHRNA4GAAALPGGFER | |
| SCHEMBL9206982 | 0.75 | CHRNB2 (0.39) | CHRNB2CHRNA4GAAALPGGFER | |
| SCHEMBL25610667 | 0.75 | CHRNB2 (0.33) | CHRNB2CHRNA4GAAALPGGFER | |
| SCHEMBL2422039 | 0.74 | GAA (0.42) | CHRNB2CHRNA4GAAALPGGFER | |
| SCHEMBL10956440 | 0.74 | CHRNB2 (0.38) | CHRNB2CHRNA4GAAALPGGFER | |
| SCHEMBL10965978 | 0.74 | CHRNB2 (0.38) | CHRNB2CHRNA4GAAALPGGFER | |
| SCHEMBL7417993 | 0.74 | HTT (0.38) | CHRNB2CHRNA4GAAALPGGFER | |
| SCHEMBL719043 | 0.73 | CHRNB2 (0.41) | CHRNB2CHRNA4GAAALPGGFER | |
| SCHEMBL4898114 | 0.73 | CHRNB2 (0.42) | CHRNB2CHRNA4GAAALPGGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| CN-109694084-A | The preparation method of DOH zeolite molecular sieve | 中国石油化工股份有限公司 | 2019-04-30 | — | — | CN | disclosed |
| US-4292190-A | ANTIFREEZES FOR COOLING SYSTEMS OF INTERNAL COMBUSTION ENGINES | BASF WYANDOTTE CORPORATION (US) | 1981-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | CHRNB2 4450/4885CHRNA4 4475/4885GAA 4/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRNB2 4559/4885CHRNA4 4613/4885GAA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.